Trial Roundup

Trial Roundup

ASH Clinical News’ Associate Editors select clinical trials to keep an eye on

Vadastuximab Talirine in Higher-Risk MDS, Low-Dose Rituximab for Acquired TTP, and more

Wednesday, March 1st, 2017
ASH Clinical News' Associate Editors select clinical trials to keep an eye on in leukemia, bleeding disorders, and lymphoma & myeloma.David Steensma, MD Dana-Farber Cancer Institute Study...

ATTRACT, PD-1 Blockade, and more

Saturday, December 31st, 2016
LEUKEMIA Selected by David Steensma, MD Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (NCT02055781) Study Design: Randomized, open-label, parallel assignment safety/efficacy study Study...

Trial Roundup: Evaluating Acalabrutinib for Hematologic Malignancies, Minimizing Menorrhagia in Women With Type 1...

Thursday, December 1st, 2016
LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute...

Introducing the Beat AML Master Trial, and more

Tuesday, November 1st, 2016
The Beat AML Master Trial Study Design: Observational, prospective cohort study Study Start Date: November 2016 Estimated Study Completion Date: November 2023 Study Status:...

Clinical Trials for Rare Diseases

Saturday, October 1st, 2016
Below, we take a look at ongoing clinical trials for rare diseases. In addition to searching for new therapeutic targets and developing novel drugs...

Measles Virus in Myeloma, SGN-CD33A in AML, and more

Tuesday, July 5th, 2016
LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML (NCT02326584) Study Design: Non-randomized, open-label, parallel-assignment safety/efficacy...

T Cell Therapy for Previously Treated Multiple Myeloma, Emicizumab in Hemophilia A Patients With...

Tuesday, March 15th, 2016
LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute A Two-Arm Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients With Myelodysplastic Syndromes (MDS)...

APEX, STORM, and more

Monday, February 22nd, 2016
LEUKEMIA Selected by David Steensma, MD A Study of the Safety and Pharmacokinetics of RO6839921, an MDM2 Antagonist, in Patients with Advanced Cancers, including Acute Myeloid...

Trial Roundup

Friday, September 25th, 2015
LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute...

ELOQUENT-2, SUSTAIN, and more

Saturday, June 20th, 2015
LEUKEMIA Selected by David Steensma, MD Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (NCT02267278) Study Design: Open-label, single-group assignment safety/efficacy study Study Start Date: January 2015 ...
Advertisement

Current Issue

March 2017, Volume 3, Issue 4

This issue takes a look at diversity in the medical education system, provides a hematology drug pipeline update, and more.